Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos
Eighty percent of patients who’ve received Genvoya so far are switched over from older Gilead regimens, while 10% have switched from non-Gilead drugs. In terms of cumulative prescriptions, the Genvoya launch is outpacing the launch of predecessor drug Stribild to date.
You may also be interested in...
O’Day Lays Out Plan For Gilead’s Continued HIV Dominance
Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.
Biktarvy, PrEP Continue Driving Gilead’s HIV Dominance
HIV remains the main growth franchise for Gilead, despite an anticipated first quarter revenue downturn due to inventory and payer mix. Biktarvy’s launch and growth in PrEP business provide multiple drivers for the franchise.
Merck To Build Case For Doravirine-Based HIV Products On Efficacy, Safety Differences
Merck adds to its stagnating HIV portfolio with US approvals of doravirine and a three-drug combo including the NNRTI, but the combo’s potential may be limited due to inclusion of an older version of tenofovir.